IGF-1 LR3 Cream is an external preparation with recombinant human insulin-like growth factor-1 LR3 (IGF-1 LR3) as the core component, claiming to promote cell growth, accelerate tissue repair, improve skin condition, and assist muscle growth. This cream is applied locally to allow IGF-1 LR3 to penetrate the skin or mucosa, bind to IGF1R on the surface of target cells, and activate intracellular signaling. Its main effects include accelerating the renewal of skin cells, muscle cells, and fibroblasts, and improving tissue repair ability. Improve muscle protein synthesis rate, inhibit protein breakdown, and promote muscle growth. Can it reduce cell death, maintain tissue homeostasis, promote glucose uptake and fat breakdown, and provide energy for cells. Claimed to reduce wrinkles, improve skin elasticity, and accelerate wound healing, it is commonly used in the field of beauty and skincare.
Our products from
IGF-1 LR3 COA
Keratinum layer: IGF-1 LR3 molecular gap under the "brick wall mortar" model
As the largest organ in the human body, the epidermis's barrier function is maintained by a "brick wall mortar" model composed of multiple layers of keratinocytes and intercellular lipids. This structure needs to maintain effective barrier against external pathogens and dynamic balance of internal moisture. However, the local application of recombinant insulin-like growth factor-1 long-acting analogs (IGF-1 LR3 Cream) is posing a systemic threat to this delicate balance by activating the protease system, interfering with lipid metabolism, and inducing abnormal cell differentiation.
Molecular basis and barrier regulation of the "brick wall mortar" model
Structure and function of the stratum corneum
The stratum corneum is located at the outermost layer of the epidermis, consisting of 5-20 layers of dead flat keratinocytes ("bricks") and intercellular lipids ("mortar"). Its core functions include:
Physical barrier: By tightly arranged keratinocytes and lipid bilayers, it prevents pathogen invasion and water loss.
Chemical barrier: Inhibits microbial growth through acidic pH (5.0-5.6) and maintains the moisturizing function of natural moisturizing factor (NMF).
Immune barrier: recognizes pathogens and initiates immune responses through Langerhans cells and Toll like receptors (TLRs).
Dynamic equilibrium of lipid bilayer
Intercellular lipids are composed of ceramides (50%), free fatty acids (25%), and cholesterol (10%) in a 1:1:1 molar ratio, forming a dense lipid bilayer. Its metabolism is regulated by the following enzyme systems:
Synthases, such as serine palmitoyltransferase (SPT), catalyze the synthesis of ceramides.
Degradation enzymes, such as sphingomyelinase (SMase), break down sphingomyelin to produce ceramides, while β - glucosinolate lipase (GBA) participates in glycosphingolipid metabolism.
Hydrolases, such as phospholipase A2 (PLA2), release free fatty acids and maintain lipid fluidity.
Dual roles of protease system
The renewal of the stratum corneum relies on precise regulation of the protease system:
Degradation effect: Serine proteases (KLK5, KLK7) and matrix metalloproteinases (MMP-1, MMP-9) break down Desmoglein-1 and Occludin, promoting keratinocyte shedding.
Repair effect: Protease inhibitors (TIMP-1, TIMP-2) prevent barrier fragility caused by excessive degradation by inhibiting MMP activity.
Differentiation regulation: After KLK5 activation, filaggrin is degraded into free amino acids, forming NMF to maintain skin moisturizing function.
Uncontrollable barrier disruption: clinical evidence and risk factors
Contradictory effects in chronic wound healing
Positive effect: promote healing, for example, IGF-1 LR3 cream can stimulate the growth of fibroblasts and keratinocytes in diabetes foot ulcers, shorten the healing time by 14 days, and increase the healing rate to 72%. Venous ulcers can promote granulation tissue formation, increasing the formation rate of granulation tissue in the wound bed by 2.1 times and increasing collagen density by 31%.
Negative effects: Long term risks such as scar formation, long-term use can lead to excessive proliferation of granulation tissue, increasing the incidence of scar formation to 18%. The sustained activation of MMPs increases the risk of recurrence as MMP-9 activity remains 57% higher than normal levels even after discontinuation.
Collagen imbalance in photoaging repair
Positive effect: Improving wrinkles, such as facial wrinkles. After 12 weeks of continuous use, the skin roughness parameter (Ra) decreased by 34% and collagen density increased by 29%. Melasma is also caused by the combination of vitamin C, which reduces the pigment intensity index (MSI) by 41% and increases skin brightness by 27%.
Negative effects: rebound effect, such as accelerated collagen loss, where collagen content drops to 68% of pre-treatment levels and wrinkle depth rebounds by 19% within 3 months after discontinuation of medication. Post inflammatory hyperpigmentation (PIH) can increase the incidence rate of PIH to 12% after long-term use, especially in Fitzpatrick IV-VI skin.
Dual regulation in inflammatory skin diseases
Positive effect: Relieve inflammation. For example, atopic dermatitis reduces SCORAD score by 52% and KLK5 expression by inhibiting Th2 type immune response. Psoriasis has a PASI score improvement rate of 63% and epidermal thickness has returned to the normal range of 81%.
Negative effects: Pathological differentiation, such as damage to the desmosome structure, can lead to a decrease in desmosome density to 54% of normal levels if used for a long time, exacerbating skin dryness and peeling. It can also cause an exacerbation of rebound, with some patients experiencing rebound within 4 weeks after discontinuing medication, and PASI scores increasing to 71% of pre-treatment levels.
Risk prevention and control strategies and future directions
Biomarkers are used to detect serum IGF-1 levels: serum IGF-1 concentration is detected by ELISA to screen suitable populations (normal range: 50-300ng/mL).
MMP/IMP ratio: Use qPCR to detect the MMP-1/IMP-1 mRNA ratio in skin tissue to assess the risk of protease imbalance (normal range: 0.5-1.5).
Gene polymorphism analysis: Detecting MMP-1-1607G/A and TIMP-1 promoter mutations through SNP typing to predict individual sensitivity to IGF-1 LR3.
Dose optimization starts from low doses: starting from 0.1-0.5 ng/mL, gradually adjusting to an effective concentration of 0.2-20 ng/mL based on tolerance.
Pulse administration: Intermittent administration method is used 2-3 times a week to reduce feedback inhibition caused by sustained activation.
Combination therapy: Used in combination with antioxidants (such as vitamin C), protease inhibitors (such as TIMP-1 mimetic peptides), or immune modulators (such as IL-4 inhibitors) to balance barrier regulation.
New delivery system and local control
The microneedle array is a soluble polymer microneedle: soluble microneedles are prepared using polylactic acid glycolic acid copolymer (PLGA) to achieve precise release from the dermis layer and reduce the risk of systemic exposure. In animal models, microneedle delivery increased local IGF-1 LR3 concentration by 5.7 times and reduced systemic exposure in the injection group by 12%.
Nanocrystalline carrier: High pressure homogenization technology is used to prepare IGF-1 LR3 nanocrystals (particle size<200 nm) to improve skin penetration efficiency. In the ex vivo skin model, the transdermal absorption rate of the nano crystalline carrier is 3.2 times that of traditional cream.
The temperature responsive hydrogel is poly (N-isopropylacrylamide) (PNIPAAm): it forms a drug pool on the skin surface through the temperature sensitive phase change characteristics. When the temperature rises to 32 ℃, the hydrogel shrinks and releases IGF-1 LR3 for 72 hours, thus reducing the frequency of administration.
Chitosan/β - glycerophosphate sodium (CS/β - GP): temperature sensitive hydrogel is formed through ionic crosslinking, and the drug is slowly released at physiological temperature. In the wound healing model, CS/β - GP hydrogel maintains the local concentration of IGF-1 LR3 within the effective range of 10-20ng/mL, promotes collagen synthesis and inhibits the expression of MMPs.
Structural modification and prodrug design
Polyethylene glycol (PEG) modification: PEG molecules (molecular weight 2000-5000) chemically couple with lysine residues of IGF-1 LR3, extending the half-life to 72 hours and reducing systemic exposure risk. In animal models, the systemic distribution of PEG-IGF-1 LR3 decreased to 18% of its unmodified form, while local therapeutic effects were comparable.
Targeted modification: Through antibody or ligand modification, precise delivery of IGF-1 LR3 to specific cell types such as fibroblasts and keratinocytes has been achieved. For example, connecting anti integrin α 5 β 1 antibodies increased drug enrichment on the surface of fibroblasts by 4.3 times.
Hydrazone bond: IGF-1 LR3 is linked to a masking group (such as p-hydroxybenzoic acid) through a hydrazone bond to form a prodrug. In the tumor microenvironment (pH<6.5) or inflammatory region (pH<7.0), hydrolysis of hydrazone bonds releases active drugs. In animal models, the tumor tissue concentration of acid sensitive prodrug was 7.2 times that of normal tissue, while systemic exposure decreased to 23% of free drug.
Esterase sensitive prodrug: IGF-1 LR3 is linked to fatty acid chains through ester bonds to form prodrugs. In the stratum corneum of the skin, esterase hydrolysis releases active drugs, achieving precise local release. In the ex vivo skin model, the transdermal absorption rate of esterase sensitive prodrug is 2.8 times that of the free drug, while the systemic distribution is reduced to 15%.
Frequently Asked Questions
Is it effective for intact and healthy skin?
+
-
It is highly likely to be ineffective. Clinical studies have shown that exogenous IGF-1 (including its analogues) is difficult to penetrate the intact stratum corneum barrier on normal, non-invasive skin and typically only works in wound environments where the skin barrier is damaged.
How can local application avoid systemic side effects?
+
-
Theory relies on precise local delivery. Local and controlled release administration through special dosage forms (such as gel and hydrogel dressings) is intended to strictly limit the biological effects in the targeted area, avoid substances entering the systemic circulation, and thus reduce the potential impact on systemic endocrine and other organs.
What is the core difference between promoting healing and traditional growth factors such as EGF?
+
-
The target of action is broader. IGF-1 LR3 not only promotes epidermal cell proliferation, but also focuses on stimulating the activity of deep dermal cells (such as fibroblasts), and may have a stronger promoting effect on collagen synthesis and granulation tissue growth, making it suitable for deeper wounds.
Why is it restricted as a cosmetic ingredient globally?
+
-
Mainly due to long-term safety concerns. Growth factors have a strong ability to promote cell division, and long-term use in healthy skin theoretically poses a risk of inducing abnormal thickening of the stratum corneum, rough skin, and even potentially promoting the growth of existing tumor cells. Therefore, countries such as China have explicitly prohibited its addition as a cosmetic ingredient.
Hot Tags: igf-1 lr3 cream, China igf-1 lr3 cream manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, octreotide injection 100 mcg, glp1 shot, etelcalcetide structure
